Fiduciary Trust’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Fiduciary Trust’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,185	Closed	-$39.2K	–	640
2023 Q1	$39.2K	Hold	21,185	–	–	﹤0.01%	610
2022 Q4	$23.5K	Hold	21,185	–	–	﹤0.01%	620
2022 Q3	$50K	Hold	21,185	–	–	﹤0.01%	600
2022 Q2	$64K	Hold	21,185	–	–	﹤0.01%	617
2022 Q1	$144K	Buy	21,185 +3,463	+20%	+$24.7K	﹤0.01%	650
2021 Q4	$148K	Hold	17,722	–	–	﹤0.01%	645
2021 Q3	$132K	Buy	17,722 +4,492	+34%	+$27.8K	﹤0.01%	637
2021 Q2	$90K	Buy	+13,230	New	+$110K	﹤0.01%	630

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Fiduciary Trust's JNCE Position: Q2 2023 in Review

Fiduciary Trust sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 21,185 shares — an estimated $39.2K sold.

Fiduciary Trust first reported a position in JNCE in Q2 2021 and held it in 8 quarters. The position peaked at $148K in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Fiduciary Trust reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Fiduciary Trust sold 21,185 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $39.2K.
Fiduciary Trust first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Fiduciary Trust's Jounce Therapeutics, Inc. Common Stock position peaked at $148K in Q4 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Fiduciary Trust's 13F filing for Q2 2023, filed 1 Aug 2023.